{
  "@context": "https://schema.org",
  "@graph": [
    {
      "@type": "Organization",
      "@id": "https://enterprisetherapeutics.com/#organization",
      "name": "Enterprise Therapeutics – Enterprise Therapeutics",
      "url": "https://enterprisetherapeutics.com/",
      "description": "In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life. Learn more Board International blend of leading corporate (Novartis Venture Fund) and more traditional venture investors (Versant, Forbion, IP Group, Epidarex, Panakes Partners) bringing individuals with a fantastic track record in Pharma and building exceptional Biotech companies."
    },
    {
      "@type": "WebPage",
      "@id": "https://directory.websdocs.com/business/enterprise-therapeutics-and-8211-enterprise-therapeutics#asg",
      "name": "Enterprise Therapeutics – Enterprise Therapeutics ASG Directory Profile",
      "url": "https://directory.websdocs.com/business/enterprise-therapeutics-and-8211-enterprise-therapeutics",
      "isPartOf": {
        "@id": "https://enterprisetherapeutics.com/#organization"
      },
      "description": "Public business information published by the WebsDocs ASG Directory."
    }
  ]
}